Evidence map›Paper›PMID 41982198›Full record

ArticleACS applied materials & interfaces2026

Engineered Lactoferrin Nanoparticle Coronas as a Tunable Platform for Immunomodulation and Antibacterial Function.

Jacob R Shaw, Ryan Yim, Jaclyn Printz, Cole Vonderheid, Mirandia Szramowski, Heidi Leung, Shruti Dharmaraj, Fanny Xu, Amanda G Oglesby, Ryan M Pearson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jacob R ShawDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.ORCID 0000-0002-5885-1006
Ryan YimDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Jaclyn PrintzDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Cole VonderheidDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Mirandia SzramowskiDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Heidi LeungDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Shruti DharmarajDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Fanny XuDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.
Amanda G OglesbyDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.ORCID 0000-0003-4440-3840
Ryan M PearsonDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, Maryland 21201, United States.ORCID 0000-0002-7857-0973

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · UNIVERSITY OF MARYLAND BALTIMORE · 2025 to 2025
$3.0M
Multimodal Nanoparticles for Severe Inflammation and SepsisR01AI192405 · UNIVERSITY OF MARYLAND BALTIMORE · 2025 to 2025
$684k
The Nathan Schnaper Intern Program in Translational Cancer ResearchR25CA186872 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · 2022 to 2025
$669k
Polymeric nanoassemblies for precise tuning of immune responsesR35GM142752 · UNIVERSITY OF MARYLAND BALTIMORE · 2025 to 2025
$386k
NCI NIH HHS P30 CA134274NCI NIH HHS R25 CA186872NIAID NIH HHS R01 AI192405NIGMS NIH HHS R35 GM142752
6 · The paper itself

Abstract

Lactoferrin (Lf) is a multifunctional endogenous glycoprotein with well-established antimicrobial and immunomodulatory activities. In this work, we report a modular nanoparticle (NP) platform in which Lf is engineered as a multilayered protein corona onto immunomodulatory poly(lactic-

Indexed as

Anti-Bacterial AgentsImmunomodulationLactoferrinNanoparticlesAnimalsEndotoxemiaEscherichia coliLipopolysaccharidesMacrophagesMicePhagocytosisPolylactic Acid-Polyglycolic Acid CopolymerRAW 264.7 CellsTumor Necrosis Factor-alphaAnti-Bacterial AgentsLactoferrinLipopolysaccharidesPolylactic Acid-Polyglycolic Acid CopolymerTumor Necrosis Factor-alphainflammationlactoferrinnanoparticlesPLGApolymerprotein coronaSepsis

Identifiers

PMID41982198
PMCPMC13157683

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.